GSK to Acquire Nuvalent for $10.6 B, Secures NSCLC Pipeline Assets
NUVL•GSK will acquire lung cancer biotech Nuvalent for $10.6 billion in cash at $124 per share, a 40% premium to its $88.49 closing price. The transaction secures two late-stage ROS1 and ALK inhibitors with FDA verdicts due September and November 2026, funded by new debt without altering guidance.
1. Deal Structure and Purchase Price
GSK will purchase all outstanding shares of Nuvalent for $124 each, valuing the transaction at $10.6 billion. The 40% premium over Nuvalent’s prior closing price will be financed through a combination of new debt facilities and existing cash reserves without impacting full-year guidance.
2. Pipeline Assets Acquired
The deal brings two late-stage non-small cell lung cancer candidates, zidesamtinib (ROS1 inhibitor) and neladalkib (ALK inhibitor), into GSK’s portfolio. Both assets hold FDA breakthrough therapy and orphan drug designations, with regulatory decisions slated for mid-September and late November 2026.
3. Strategic Rationale
This acquisition underscores GSK’s shift toward high-value oncology assets under CEO Luke Miels, aiming to bolster revenue ahead of patent expiries in other franchises. The addition of multi-blockbuster potential candidates supports GSK’s goal to expand its cancer pipeline and drive growth into 2027 and beyond.
